
Commentary|Videos|July 24, 2025
Updated Findings From CheckMate-816 for Neoadjuvant Nivolumab Plus Chemo in Resectable NSCLC
Author(s)Wade T. Iams, MD, Jessica Donington, MD, MSCR
Fact checked by: Chris Ryan
Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss updated findings for neoadjuvant nivolumab plus chemotherapy in resectable NSCLC.
Advertisement
Episodes in this series

Advertisement
Related to this article

IL-1β blockade with canakinumab was well tolerated and reduced nodule size in patients with high-risk indeterminate pulmonary nodules.

The CHMP backed sintilimab plus chemotherapy in NSCLC; the FDA issued a complete response letter for the regimen in 2022.

Quality Improvement and EGFR-Mutant Lung Cancer Survivorship Research Help Shape Fellowship Training
Christine Ann Garcia, MD, MPH, discusses error review in fellowship training, survivorship in EGFR+ lung cancer, and nontraditional career paths.

Alissa Cooper, MD, reviews new data for established and emerging antibody-drug conjugate targets in non–small cell lung cancer and argues that payload innovation and better patient selection are the field's greatest needs.

The FDA has approved neladalkib for previously treated, ALK-positive, locally advanced or metastatic non-small cell lung cancer.

The FDA cited the lack of a significant OS benefit in HARMONi for ivonescimab plus chemotherapy after EGFR TKI therapy in NSCLC.

The top 5 OncLive TV videos of the week cover insights in HER2+ breast cancer, NSCLC, ovarian cancer, prostate cancer, and sarcoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Neladalkib for Locally Advanced or Metastatic ALK+ NSCLC
2
Pertuzumab Biosimilar Gains FDA Approval for HER2+ Breast Cancer
3
FDA Removes Limitations of Use for Liso-Cel in Primary Central Nervous System Lymphoma
4
FDA Accepts sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis
5

